# Design, Synthesis, and Biological Evaluation of Isoform Selective Inhibitor

# Discovery of Mitochondrial Protein Modulator 

# Development of Metaloprotein Inhibitor 

# Mitochondrial/Bacterial targeted strategies

# Computer/AI-aided Drug Optimization

# ADME/Tox-based Drug Optimization

Our Drug Targets

Drug Development

CaV1.3 as therapeutic target for neuronal diseases 

Mitochondrial chaperone protein TRAP1 as a therapeutic target for cancers 

Delocalized lipophilic cations as a mitochondria accumulation reagents

Contribution of JAK1/STAT3 and ENPP2 to Inflammatory and Fibrotic Diseases

isoQC as an target for cancer immunotherapy via modification of CD47-SIRPa axis